ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

CD Bioparticles Announces Lipofection Reagents in Gene Expression

By: Get News
CD Bioparticles recently introduced a series of Lipofection Reagents for bio-research applications.

New York, USA - November 29, 2022 - CD Bioparticles, a leading manufacturer and supplier of various drug delivery products and services, recently introduced a series of Lipofection Reagents for bio-research applications, including but not limited to the BiochemFect Transfection Reagent, BiochemFect Gold Transfection Reagent, Insect Transfection Reagent, and HeLa Transfection Reagent.

Specializing in a range of formulation and drug delivery technologies, CD Bioparticles owns strong and broad expertise and years of experience in the drug delivery field. To support scientists' gene expression research, CD Bioparticles now offers various Lipofection Reagent options.

For example, the BiochemFect Transfection Reagent is based on an innovative biochemical approach. It contains a lipid moiety and a cationic moiety that allow the binding of nucleic acids, thus achieving delivery within cells. Due to its unique properties, BiochemFect releases large amounts of DNA in the cytosol, thereby further enhancing DNA nuclear delivery. As a result, BiochemFect is very effective at low doses of nucleic acids, due to lessening cationic lipids are used, avoiding potential side effects.

Moreover, the BiochemFect Gold Transfection Reagent allows the transfection of all types of nucleic acids at high efficiency. BiochemFect Gold delivers large amounts of nucleic acids, resulting in higher protein expression compared to other transfection reagents. Meanwhile, it is completely biodegradable and has no interference with cellular mechanisms. Thus, high cell viability is maintained in every experiment and any potential secondary effects are avoided.

Another example is the Insect Transfection Reagent, which is a powerful TEE-based tool designed for efficient and reproducible transfection of insect cells. It is suitable for the delivery of all types of nucleic acids and is used in different applications, for example, the production of recombinant proteins utilizing the baculovirus expression system. This reagent has been used effectively with a variety of insect cells, such as Ag55, Anso, Asd43, Bm5, Cl8, Cpp512, High5, IPBL-SF21, Kc167, Ld652, Mos20, S2, Sf9, SL-2, SL-3, and SPC-SL52.

While HeLa Transfection Reagent is specially developed for efficient transfection of HeLa cell lineage. Its design allows the efficient transportation of highly compact nucleic acids in HeLa cells. Composed of biodegradable lipids, HeLa Transfection Reagents are highly active and ready to use.

"For pharma and biotech scientists focusing on gene expression research, they are looking for integrated solutions that adapt to early development and clinical trials," said Dr. Robin J. Watts, the scientific officer at the R&D department of CD Bioparticles. "By offering these transfection reagents, we will demonstrate our deep expertise across a range of topics, from laboratory research to drug delivery technologies, helping our customers accelerate innovations and speed up scientific breakthroughs."

For more information about Lipofection Reagents or other transfection products, please visit CD Bioparticles at https://www.cd-bioparticles.net.

About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. It also provides contract research services for drug delivery formulation, formulation feasibility study, process development & scale-up, formulation characterization, as well as analytical and non-clinical services.

Media Contact
Company Name: CD Bioparticles
Contact Person: Richard J. Gray
Email: Send Email
Phone: 1-631-346-0027
Country: United States
Website: https://www.cd-bioparticles.net



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.